Seaport Therapeutics opened lower at $20.99, compared with its previous close of $21.31. In the last trading session, the stock traded between $19.94 and $21.35. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Seaport Therapeutics is now worth
$ 101.13
Giving a profit of
$ 1.13 (1.13%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.25 (-5.85%)
Day High
$21.35
Day Low
$19.94
Day Open
$20.99
Prev Close
$21.31
Volume
1,75,838
1W Return
-4.15%
1M Return
17.37%
3M Return
-14.35%
6M Return
31.57%
1Y Return
1.13%
Fundamentals
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
3.05
PEG Ratio
-
ROE
-
ROCE
-31.62%
EPS (TTM)
-
Investment Returns
1 Week
-4.15%
1 Month
17.37%
3 Months
-14.35%
6 Months
31.57%
9 Months
1.13%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
6Nov
JP Morgan raises Seaport Therapeutics price target to $41, maintains Overweight
JP Morgan analyst Tessa Romero raised the price target for Seaport Therapeutics to $41. The new target is up from the previous level of $40. The Overweight rating on the stock remains unchanged.
7 days ago
9Oct
Seaport Therapeutics to present GlyphAgo Phase 1 data at ECNP Congress
Seaport Therapeutics to present first scientific data on GlyphAgo at ECNP Congress in Munich, October 10-13, 2026. Phase 1 data confirms 6.8-fold increase in bioavailability versus unmodified agomelatine. PK variability for GlyphAgo ranged from 12.9% to 29.7% for AUC, compared to up to 350.1% for agomelatine. Trial involved 174 healthy volunteers; no liver-related adverse events or significant lab changes reported. Phase 2a trial in anxiety disorder ongoing with topline data expected early 2028.
